Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

PMID:
22266222
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.

Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.

PMID:
21308717
[PubMed - indexed for MEDLINE]
3.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

PMID:
24002508
[PubMed - indexed for MEDLINE]
4.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

PMID:
19359544
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

PMID:
23493310
[PubMed - indexed for MEDLINE]
Free Article
6.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH.

Cancer Discov. 2013 Sep;3(9):1020-9. doi: 10.1158/2159-8290.CD-13-0226. Epub 2013 Jun 18.

PMID:
23779130
[PubMed - indexed for MEDLINE]
7.

Androgen receptor antagonists in castration-resistant prostate cancer.

Rathkopf D, Scher HI.

Cancer J. 2013 Jan-Feb;19(1):43-9. doi: 10.1097/PPO.0b013e318282635a. Review.

PMID:
23337756
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
[PubMed - indexed for MEDLINE]
9.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
[PubMed - indexed for MEDLINE]
10.

Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.

Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.

Int J Cancer. 2013 Nov;133(9):2225-33. doi: 10.1002/ijc.28202. Epub 2013 May 9.

PMID:
23575870
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
[PubMed - indexed for MEDLINE]
12.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

PMID:
23966621
[PubMed - indexed for MEDLINE]
13.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.

PMID:
20398925
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM.

Cancer Res. 2009 Aug 15;69(16):6522-30. doi: 10.1158/0008-5472.CAN-09-1111. Epub 2009 Aug 4.

PMID:
19654297
[PubMed - indexed for MEDLINE]
Free Article
15.

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C.

J Biol Chem. 2013 Jul 5;288(27):19359-69. doi: 10.1074/jbc.M113.477216. Epub 2013 May 16.

PMID:
23687298
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

PMID:
22027692
[PubMed - indexed for MEDLINE]
Free Article
17.

Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC, Liao S.

Cancer Sci. 2011 Nov;102(11):2022-8. doi: 10.1111/j.1349-7006.2011.02043.x. Epub 2011 Aug 18. Erratum in: Cancer Sci. 2013 Jan;104(1):142. Huo, Chiech [corrected to Huo, Chieh].

PMID:
21781227
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
[PubMed - indexed for MEDLINE]
19.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

PMID:
23117885
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Resistance emerges to second-generation antiandrogens in prostate cancer.

Nelson WG, Yegnasubramanian S.

Cancer Discov. 2013 Sep;3(9):971-4. doi: 10.1158/2159-8290.CD-13-0405.

PMID:
24019330
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk